BRISTOL MYERS SQUIBB CO
BMYPharma & biotechbms.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 29, 2026
Next reportFebruary 3, 2027after close · forecast 1.53 $/share
Revenue
$13.07B
▲ +6.9% vs prior year YoY
Net income
$2.16B
▼ -1.8% vs prior year YoY
EPS
1.05$
▼ -2.8% vs prior year YoY
Net margin
16.5%
▼ -1.5 pp vs prior year YoY
Revenue▲ +6.9%
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -1.8%
EPS▼ -2.8%
Financial statements
View 10-Q filed October 29, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B | $12.97B | $13.07B | ▲ +6.9% |
| Gross profit | $7.53B | $8.17B | $8.90B | $8.79B | $8.41B | $8.07B | $9.25B | $8.92B | ▲ +1.5% |
| Operating income | — | — | — | — | — | — | — | — | — |
| Net income | $72.00M | $2.46B | $1.31B | $2.20B | $1.09B | $2.68B | $3.32B | $2.16B | ▼ -1.8% |
| R&D | $3.19B | $2.26B | $2.58B | $2.53B | $2.59B | $2.65B | $2.96B | $2.37B | ▼ -6.4% |
| EPS (diluted) | — | 1.20 $ | 0.64 $ | 1.08 $ | — | 1.31 $ | 1.62 $ | 1.05 $ | ▼ -2.8% |
| Margins (% of revenue) | |||||||||
| Gross | 61.0 % | 72.9 % | 72.5 % | 71.9 % | 67.2 % | 70.2 % | 71.3 % | 68.3 % | ▼ -3.6 pt |
| Operating | — | — | — | — | — | — | — | — | — |
| Net | 0.6 % | 21.9 % | 10.7 % | 18.0 % | 8.7 % | 23.3 % | 25.6 % | 16.5 % | ▼ -1.5 pt |
| Balance sheet | |||||||||
| Assets | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B | $86.48B | $87.63B | $88.77B | ▼ -8.4% |
| Liabilities | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B | $66.37B | $65.31B | $65.37B | ▼ -16.5% |
| Equity | $16.39B | $17.45B | $17.49B | $18.60B | $18.51B | $20.10B | $22.32B | $23.40B | ▲ +25.8% |
| Cash | $10.35B | $10.88B | $12.60B | $15.73B | $10.21B | $9.57B | $8.72B | $9.57B | ▼ -39.1% |
| Capital | |||||||||
| Shares outstanding | 2.03B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | 2.04B | ▲ +0.4% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.